Tidepool Highlights New Clinical Research and Women’s Health Initiatives at ADA 2026
Tidepool, a nonprofit organization focused on advancing diabetes technology and data-driven healthcare solutions, showcased a series of new clinical findings and research initiatives during the American Diabetes Association (ADA) 86th Scientific Sessions. The presentations underscored the organization’s commitment to improving diabetes management through real-world data, expanding healthcare access in underserved communities, and addressing longstanding gaps in women’s health research.
The company’s participation at one of the largest diabetes-focused scientific gatherings highlighted how digital health tools, continuous glucose monitoring (CGM), and patient-centered research can contribute to more personalized and equitable diabetes care.
Real-World Data Demonstrates Improvements in Resource-Limited Care Settings
One of the key presentations focused on the use of data-driven diabetes management programs in healthcare environments with limited resources. As healthcare systems continue to face staffing shortages and increasing patient demands, clinicians are seeking innovative approaches that enable them to deliver effective care while maximizing available resources.
During a poster presentation at ADA 2026, Tidepool Medical Advisor Dr. Sushma Reddy presented findings from a 24-week Diabetes Care Management Program (DCMP) designed to support adults living with uncontrolled type 2 diabetes. The program was implemented within a resource-constrained healthcare setting and relied heavily on remote patient monitoring technologies.
The initiative utilized continuous glucose monitoring data integrated through Tidepool’s TIDE clinic dashboard, allowing healthcare teams to monitor patient progress remotely and identify individuals who required immediate intervention or educational support. Rather than applying the same level of attention to every patient regardless of need, the system enabled clinicians to prioritize outreach efforts based on real-time glucose trends and risk indicators.
According to the study findings, participants experienced significant improvements in key diabetes management metrics over the course of the program. Patients achieved an average reduction of 1.59 percentage points in HbA1c levels, a widely used measure of long-term blood glucose control. Additionally, participants increased their Time in Range by 13.4%, indicating they spent more time maintaining healthy glucose levels.
The results suggest that remote monitoring and targeted patient engagement strategies can deliver meaningful clinical improvements even in healthcare environments facing financial and staffing constraints.
Dr. Reddy emphasized that the combination of CGM technology and intelligent data tools allows care teams to focus their efforts where they can have the greatest impact. By quickly identifying patients who require immediate support, clinicians can intervene earlier, provide timely education, and improve outcomes without overwhelming limited healthcare resources.
The findings also contribute to growing evidence that digital health platforms can help reduce disparities in diabetes care by expanding access to specialist-level monitoring and support beyond traditional clinical settings.
Advancing Women’s Health Research in Diabetes
In addition to presenting clinical outcomes data, Tidepool used ADA 2026 as a platform to spotlight a major initiative focused on women’s health and diabetes research.
Historically, women’s unique physiological experiences—including menstrual cycles, pregnancy, perimenopause, and menopause—have been underrepresented in diabetes research and treatment development. As a result, many women living with diabetes continue to face challenges that are not fully addressed by existing clinical guidelines and technologies.
At the DiabetesMine D-Data ExChange event held alongside ADA 2026, Maya Friedman, Tidepool’s Director of Product Design and User Experience, discussed the company’s efforts to close this research gap.
Friedman highlighted preliminary findings from menstrual cycle research conducted in collaboration with Diabetes Center Berne. The research explores how hormonal fluctuations influence glucose patterns and insulin needs throughout different phases of the menstrual cycle.
Building on these findings, Tidepool outlined its vision for a large-scale women’s health initiative that was introduced during the Milken Institute Women’s Health Network event last fall. The project aims to create one of the largest opt-in, anonymized databases combining biometric information with diabetes device data.
The initiative is being developed in partnership with health technology companies, including ŌURA, and seeks to generate a comprehensive dataset capable of revealing patterns that have historically been difficult to study.
By bringing together information from wearable devices, glucose monitoring systems, and other health technologies, researchers hope to gain deeper insights into how biological changes across different life stages affect diabetes management.
Friedman noted that women have long been underserved in diabetes research despite representing a substantial portion of the global diabetes population. She emphasized that collecting large-scale, multi-signal data could help researchers generate objective evidence needed to guide the development of more personalized therapies, treatment approaches, and digital health solutions.
The initiative represents a broader industry effort to ensure that future diabetes technologies better reflect the diverse experiences of patients and support individualized care across all stages of life.
Exploring Smarter Meal Management for Automated Insulin Delivery Systems
Another important area of research presented at ADA 2026 focused on reducing the burden of meal tracking for individuals living with type 1 diabetes.
Meal logging remains one of the most challenging and time-consuming aspects of diabetes management. Many users of automated insulin delivery (AID) systems are required to estimate carbohydrate intake and manually enter meal information throughout the day. While these actions help optimize insulin dosing, they can also contribute to significant mental fatigue and treatment burden.
To address this challenge, researchers from Stanford University, Replica Health, and Tidepool collaborated on a study examining how personalized meal records could improve glucose outcomes while reducing the need for highly precise meal logging.
The study analyzed meal-logging behavior over a 40-day period among participants who reported different approaches to tracking food intake. Some participants consistently entered detailed and accurate carbohydrate counts, while others used rough estimates or mixed approaches.
Researchers discovered that repeated meals were associated with improved post-meal glucose outcomes, even when carbohydrate estimates were not perfectly accurate. The findings suggest that individuals may benefit from leveraging historical meal data rather than relying solely on precise carbohydrate counting every time they eat.
These insights could have important implications for the future development of automated insulin delivery algorithms. By learning from an individual’s real-world eating habits and glucose responses, AID systems may eventually provide more personalized insulin recommendations while requiring fewer manual inputs from users.
Kelly Watson, Tidepool’s Chief Product Officer, explained that reducing the burden associated with meal management remains a major priority for the company. She noted that the research supports a future in which diabetes technologies can adapt to individual behaviors and experiences rather than requiring users to maintain constant precision.
The study aligns with broader efforts across the diabetes technology industry to make automated insulin delivery systems more intuitive, personalized, and easier to use in everyday life.
Building a More Connected and Personalized Diabetes Ecosystem
Collectively, the studies and initiatives presented by Tidepool at ADA 2026 reflect a broader vision of connected, data-driven healthcare.
From improving outcomes in underserved communities to advancing women’s health research and enhancing automated insulin delivery systems, the organization’s work centers on using real-world data to address practical challenges faced by people living with diabetes.
Tidepool CEO and Co-founder Brandon Arbiter emphasized the importance of collaboration among researchers, clinicians, technology developers, and patients in driving meaningful progress across the diabetes landscape.
According to Arbiter, events such as the ADA Scientific Sessions provide valuable opportunities for stakeholders throughout the diabetes community to exchange ideas, share evidence, and advocate for innovations that improve everyday care.
He noted that Tidepool remains focused on identifying opportunities where technology and data can create the greatest impact for both individual users and the broader healthcare system. The company’s ongoing efforts seek to demonstrate how accessible health data can support more personalized treatment decisions, improve clinical outcomes, and foster greater equity in diabetes care.
As diabetes technology continues to evolve, the research presented at ADA 2026 highlights the growing role of real-world evidence in shaping future innovations. Whether through remote patient monitoring, advanced analytics, women’s health research, or next-generation automated insulin delivery systems, Tidepool aims to help create a healthcare ecosystem that better serves the diverse needs of people living with diabetes around the world.
This version is expanded, journalistic in tone, and exceeds 1,000 words while preserving the key information from the original announcement.
About Tidepool
Tidepool is a recognized innovator in diabetes software on a mission to make diabetes data more accessible, actionable, and meaningful for people with diabetes, their care teams, and researchers. Founded in 2013, Tidepool hosts a suite of software tools for people with diabetes and the clinics that serve them, including Tidepool+, Tidepool Mobile, Tidepool Uploader, and the FDA-cleared Tidepool Loop. Through strategic industry partnerships, Tidepool Loop is commercially available via partner-developed adaptations, such as the twiist™ AID System powered by Tidepool, now available in the iOS App Store. Built with enterprise-grade security, the Tidepool platform is HIPAA-compliant and SOC 2 Type II-compliant
